Conditions: HIV
Keywords: HIV
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 13
Healthy volunteers: no

Brief summary:
This is a phase I, open label, prospective, two phase pharmacokinetic study. Subjects currently attending for HIV care at St. Mary's Hospital, London will be eligible.

Detailed description:
The study will describe the steady state pharmacokinetic parameters and short term safety of maraviroc/darunavir/ritonavir dosed at 150/800/100 mg once daily with and without tenofovir/emtricitabine 245/200 mg once daily in HIV-1 infected subjects.

Fifteen HIV-1 infected subjects will be recruited. Eligible subjects will currently be receiving antiretroviral therapy comprising:

* tenofovir/emtricitabine 245/200 mg daily plus
* darunavir/ritonavir 800/100 mg daily

On day 1, subjects will modify their current antiretroviral therapy to the following:

* tenofovir/emtricitabine 245/200 mg daily plus
* darunavir/ritonavir 800/100 mg daily plus
* maraviroc 150 mg daily On day 10 subjects will undergo an intensive pharmacokinetic visit.

On day 11, subjects will modify their current antiretroviral therapy to the following:

* darunavir/ritonavir 800/100 mg daily plus
* maraviroc 150 mg daily (i.e. tenofovir/emtricitabine will be discontinued) On day 20 subjects will undergo an intensive pharmacokinetic visit. Following completion of this study phase, subjects will recommence their usual antiretroviral treatment regimen and attend for a study follow up visit.

Arms:
arm 1: Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada

Interventions: intervention 1: Maraviroc intervention 2: Truvada intervention 3: Darunavir
Intervention descriptions: intervention 1: Maraviroc 150 mg daily intervention 2: daily until 10. day then stop intervention 3: daily until 10. day then stop

Protocol document: